Contents hide 1 About Aumolertinib 2 Approval 3 Dosage 3.1 Dosage adjustment About Aumolertinib Aumolertinib (previously known as almonertinib) is a EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). Aumolertinib sold under the brand name Ameile.  Aumolertinib sold under the brand name 阿美乐 in china. Approval In March 2020 aumolertinib was approved in China, on the basis of APOLLO (ClinicalTrials.gov identifier: NCT0298110), for the treatment of patients with advanced NSCLC and an EGFR T790M mutation. Dosage The recommended dose of this product is 110 mg, taken orally once … Continue reading Ameile (Aumolertinib)